Partner

Articles & Insights / Mineral Formulations

Choosing Magnesium Forms for a Practical and Defensible Formulation

Magnesium form selection is a formulation decision involving elemental content, ingredient mass, solubility, sensory quality, tolerability and supporting evidence. A salt name alone cannot establish the performance of the finished product.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Distinguish compound mass from elemental magnesium
  • Make the format feasible
  • Separate solubility from absorption

Distinguish compound mass from elemental magnesium

The declared magnesium amount and the mass of a magnesium-containing ingredient are different quantities. Calculate the required ingredient using its actual elemental content and assay basis, including the effects of hydration or carrier materials where relevant. Do not compare two products using total salt mass when their labels declare elemental magnesium.

For illustration, delivering 150 mg of elemental magnesium requires 1,000 mg of a hypothetical ingredient containing 15% magnesium, but 375 mg of one containing 40%. The illustration plots this arithmetic. Neither percentage is assigned to a named commercial salt, and 150 mg is not a recommended dose.

Explore the scienceMineral Formulations
Hypothetical ingredient mass for a 150 mg elemental target
1,000 mg ingredient

150 mg ÷ 0.15 = 1,000 mg

Illustrative fractions, not assigned to named commercial salts. This is not dose advice.
An illustrative 150 mg elemental target needs 1,000 mg of a hypothetical 15% source or 375 mg of a 40% source. No percentages are assigned to commercial salts; this is not dose advice.

Make the format feasible

The required mass affects tablet size, number of units, sachet weight and room for other nutrients. A source with a lower elemental fraction may suit one format but be difficult to accommodate in another. Powders, chewables, liquids and tablets impose different demands on taste, dispersibility and processing.

Define the intended serving before developing a flavour system or selecting tooling. A prototype can taste acceptable at a low experimental concentration yet become impractical at the final elemental target. Formulation screening should use realistic ingredient loading from the outset.

Separate solubility from absorption

Solubility depends on the specific material and test conditions, including pH. A visually dispersed powder is not necessarily completely dissolved, and solubility in water does not establish human bioavailability. Compare finished formulations under relevant conditions and describe what the experiment actually measures.

NIH’s magnesium fact sheet provides context on forms and absorption. Human comparative studies also show that study design, endpoint, dose and preparation matter. A finding for particular products should not be extended to every product carrying the same salt name or to untested clinical benefits. R58R59

Consider tolerance and intended use

The quantity of unabsorbed magnesium and the formulation can influence gastrointestinal effects. Tolerability must be considered for the intended population and amount, alongside total magnesium from other relevant sources. Nutrient adequacy, clinical treatment and laxative use are different product purposes and should not be combined in one undifferentiated claim.

Avoid assigning a fixed percentage absorption or a universal therapeutic advantage to a form without suitable evidence. A sleep, cognition or muscle-related claim requires its own substantiation and regulatory assessment. Selecting a fashionable form is not a substitute for defining the product’s intended benefit.

Investigate interactions within the combination

Magnesium ingredients can affect pH, moisture behaviour, flavour and the stability of other constituents. In an effervescent or drink format, their interactions with acids and other salts may change dissolution, gas generation and sensory properties. A change in source can alter more than the magnesium assay.

A hypothetical magnesium and vitamin blend could remain within mineral content limits while developing an unacceptable taste or a decline in a sensitive vitamin. Test the relevant attributes individually. A total elemental result does not describe the physical or chemical state of every component.

Build a balanced selection package

Compare candidate forms using a consistent matrix covering elemental loading, permitted status, processing, sensory quality, stability and the evidence relevant to the proposed claim. Include cost per declared elemental amount and per finished serving, rather than raw-material price per kilogram alone.

Stabicon can support source comparison and formulation development that connect the chosen magnesium ingredient to a practical format and a defensible evidence package. The final selection should explain why it fits the product brief under the intended market requirements.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R58
    NIH Office of Dietary Supplements Magnesium

    Health-professional fact sheet. Scientific context for magnesium forms, intake and absorption.

  2. R59
    Assessment of Bioavailability of Magnesium from Citrate and Oxide

    Primary human research. PubMed PMID 32162607. Findings depend on the tested preparations, design and endpoints.

  3. R21
    FSSAI Health Supplements and Nutraceuticals Standards

    Official regulations portal. Verify current amendments, permitted ingredients, levels and category-specific requirements.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin